Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock

Core Points - Olema Pharmaceuticals, Inc. has announced a public offering of 10,000,000 shares of its common stock priced at $19.00 per share [1] - The gross proceeds from the offering are expected to be approximately $190.0 million before deductions [2] - The offering is expected to close on November 20, 2025, subject to customary closing conditions [2] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [1] - The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials [6] - Olema is also developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, which is in a Phase 1 clinical study [6]